Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
Hans von der Maase(University of Copenhagen), PierFranco Conte(University of Padua), Irene Tomlin(Aarhus University Hospital), T. Oliver(Aarhus University Hospital), J.T. Roberts(Aarhus University Hospital), I. Bodrogi(Aarhus University Hospital), Pedro Sánchez‐Rovira(Complejo Hospitalario de Jaén), Peter Albers(Düsseldorf University Hospital), Carla Visseren‐Grul(Aarhus University Hospital), Luigi Dogliotti(Aarhus University Hospital), Pierre Kerbrat(Aarhus University Hospital), Peter Wersäll(KU Leuven), Christian Lippert(Aarhus University Hospital), Alexander Knuth(National Center for Cancer Care and Research), Steen Werner Hansen(Aarhus University Hospital), Simon Cleall(Aarhus University Hospital), D. Roychowdhury(Aarhus University Hospital), Malcolm J. Moore(University Health Network)
Cited by 2,286
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k